Literature DB >> 10936884

Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo.

A M Fagan1, D M Holtzman.   

Abstract

The genetic association between the E4 isoform of apolipoprotein E (apoE) and increased risk for Alzheimer's disease (AD) has prompted interest in the neurobiology of apoE and the possible relationship between lipoprotein metabolism in the brain and neurodegenerative disease. ApoE, a product of astrocytes, is abundant in brain and in cerebrospinal fluid (CSF) where it is found in lipoproteins the size of large plasma high-density lipoproteins (HDL). Cultured astrocytes also secrete apoE/HDL, although the lipid and apoprotein composition of these nascent particles differs from that found in CSF, suggesting possible functional differences. In vitro studies have demonstrated isoform-specific effects of apoE on neurite outgrowth, neuronal plasticity, neurotoxicity, lipid peroxidation, oxidative injury, binding to cytoskeletal proteins, and interactions with amyloid-beta (Abeta), a primary component of senile plaques in AD. A number of these proposed functions have also been assessed in apoE -/- mice and transgenic mice expressing human apoE3 or apoE4. Importantly, analysis of transgenic mice overexpressing a mutant form of the human amyloid precursor protein (APP(V717F)) in the presence of mouse apoE, no apoE, or human apoE3 or E4 has demonstrated a critical and isoform-specific role for apoE in neuritic plaque formation, a pathologic hallmark of AD. Together, these data have provided important clues as to possible mechanism(s) by which apoE genotype modifies AD risk. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936884     DOI: 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  22 in total

Review 1.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases.

Authors:  Xinwen Zhang; Di Hu; Yutong Shang; Xin Qi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-03-18       Impact factor: 5.187

3.  Chronic thrombin exposure results in an increase in apolipoprotein-E levels.

Authors:  Molina Mhatre; Kenneth Hensley; Albert Nguyen; Paula Grammas
Journal:  J Neurosci Res       Date:  2006-08-01       Impact factor: 4.164

4.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.

Authors:  Jean-Cosme Dodart; Robert A Marr; Milla Koistinaho; Beth M Gregersen; Seema Malkani; Inder M Verma; Steven M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

Review 5.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

6.  Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells.

Authors:  Jie Zhou; Juan Chen; Youmei Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

7.  Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects.

Authors:  Haixiang Su; Mervyn Gornitsky; Guoyan Geng; Ana M Velly; Howard Chertkow; Hyman M Schipper
Journal:  Age (Dordr)       Date:  2008-01-04

8.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

9.  The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.

Authors:  J-C Lambert; N Coyle; C Lendon
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

Review 10.  Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.